Alberto R De Caterina1,2, Andrew R Harper2,3, Florim Cuculi21Istituto Scienze della Vita, Scuola Superiore Sant&#39;Anna, Pisa, Italy; 2Oxford University Hospitals, Oxford; 3Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United KingdomAbstract: Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension. Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached. For this reason, the search for new antihypertensive agents is still ongoing. Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control. The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre-clinical and clinical studies.Keywords: azilsartan medoxomil, angiotensin receptor blocker, hypertensio
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.